ERBB2 and breast carcinoma: By contrast, in the FVB/N MMTV-Neu (Neu+) model, which represents the HER2-amplified subtype of human breast cancer (8), animals had late mammary tumor occurrence (∼20 weeks after birth) and slower tumor growth rate, which was accompanied with mild reduction of grip strength, rotarod performance, and muscle contraction force (9).